- Home
- SKE vs CLDX Comparison
SKE vs CLDX Comparison
Compare SKE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- CLDX
- Stock Information
- Founded
- SKE 1979
- CLDX N/A
- Country
- SKE Canada
- CLDX United States
- Employees
- SKE N/A
- CLDX N/A
- Industry
- SKE Precious Metals
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SKE Basic Materials
- CLDX Health Care
- Exchange
- SKE Nasdaq
- CLDX Nasdaq
- Market Cap
- SKE 2.1B
- CLDX 1.9B
- IPO Year
- SKE N/A
- CLDX 2008
- Fundamental
- Price
- SKE $17.69
- CLDX $25.76
- Analyst Decision
- SKE
- CLDX Buy
- Analyst Count
- SKE 0
- CLDX 10
- Target Price
- SKE N/A
- CLDX $43.80
- AVG Volume (30 Days)
- SKE 600.5K
- CLDX 889.9K
- Earning Date
- SKE 11-13-2025
- CLDX 11-10-2025
- Dividend Yield
- SKE N/A
- CLDX N/A
- EPS Growth
- SKE N/A
- CLDX N/A
- EPS
- SKE N/A
- CLDX N/A
- Revenue
- SKE N/A
- CLDX $2,599,000.00
- Revenue This Year
- SKE N/A
- CLDX N/A
- Revenue Next Year
- SKE N/A
- CLDX N/A
- P/E Ratio
- SKE N/A
- CLDX N/A
- Revenue Growth
- SKE N/A
- CLDX N/A
- 52 Week Low
- SKE $7.32
- CLDX $14.40
- 52 Week High
- SKE $20.77
- CLDX $29.05
- Technical
- Relative Strength Index (RSI)
- SKE 53.85
- CLDX 53.72
- Support Level
- SKE $16.75
- CLDX $23.47
- Resistance Level
- SKE $18.44
- CLDX $25.03
- Average True Range (ATR)
- SKE 0.65
- CLDX 1.33
- MACD
- SKE 0.20
- CLDX 0.04
- Stochastic Oscillator
- SKE 74.66
- CLDX 75.13
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.